Lexaria Bioscience Corp. (LEXX): Cost of Revenue
$2.7K
Year ended 2025-08-31
$0
Trailing 12 months to 2026-05-31
-66.4%
3-year compound annual growth
-51.3%
5-year compound annual growth
-21.3%
10-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-08-31 | $2.7K | -43.6% | 2025-11-28, From 2024-09-01 |
| 2024-08-31 | $4.8K | -84.7% | 2025-11-28, From 2023-09-01 |
| 2023-08-31 | $31.5K | -56.2% | 2024-11-26, From 2022-09-01 |
| 2022-08-31 | $71.8K | -59.0% | 2023-11-20, From 2021-09-01 |
| 2021-08-31 | $175.3K | +76.4% | 2022-11-28, From 2020-09-01 |
| 2020-08-31 | $99.4K | +334.1% | 2021-11-29, From 2019-09-01 |
| 2019-08-31 | $22.9K | -9.1% | 2020-10-15, From 2018-09-01 |
| 2018-08-31 | $25.2K | -15.3% | 2019-11-14, From 2017-09-01 |
| 2017-08-31 | $29.8K | -34.8% | 2018-11-14, From 2016-09-01 |
| 2016-08-31 | $45.6K | +52.6% | 2018-11-14, From 2015-09-01 |
| 2015-08-31 | $29.9K | n/a | 2016-11-29, From 2014-09-01 |
| 2014-08-31 | $0 | n/a | 2015-11-27, From 2013-09-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | 2025-08-31 | $2.7K | -43.6% |
| Polomar Health Services, Inc. (PMHS) | 2025-12-31 | $188.1K | +573.8% |
| BioXcel Therapeutics, Inc. (BTAIQ) | 2025-12-31 | $164.0K | -92.3% |
| Hyperion Defi, Inc. (HYPD) | 2025-12-31 | $303.3K | -92.3% |
| Onconetix, Inc. (ONCO) | 2025-12-31 | $182.5K | -87.6% |
| PMGC Holdings Inc. (ELAB) | 2025-12-31 | $404.8K | n/a |
| Silence Therapeutics plc (SLN) | 2025-12-31 | $215.0K | -98.2% |
| Rafael Holdings, Inc. (RFL) | 2024-07-31 | $154.0K | n/a |
| Quantum Cyber N.V. (QUCY) | 2025-12-31 | $147.3K | -53.8% |
Compare LEXX, PMHS, BTAIQ, HYPD side by side · Screen every company in Pharmaceutical Preparations ↗